WO2009100716A2 - Implantierbare nanopartikel-enthaltende produkte - Google Patents
Implantierbare nanopartikel-enthaltende produkte Download PDFInfo
- Publication number
- WO2009100716A2 WO2009100716A2 PCT/DE2009/000196 DE2009000196W WO2009100716A2 WO 2009100716 A2 WO2009100716 A2 WO 2009100716A2 DE 2009000196 W DE2009000196 W DE 2009000196W WO 2009100716 A2 WO2009100716 A2 WO 2009100716A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medical device
- cancer
- carcinoma
- particles
- tumors
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 79
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 60
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 239000002245 particle Substances 0.000 claims description 75
- 239000006249 magnetic particle Substances 0.000 claims description 50
- -1 polycarbourethane Polymers 0.000 claims description 44
- 230000005291 magnetic effect Effects 0.000 claims description 41
- 239000000499 gel Substances 0.000 claims description 38
- 229920001577 copolymer Polymers 0.000 claims description 34
- 229920000642 polymer Polymers 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 24
- 239000007921 spray Substances 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 21
- 239000013543 active substance Substances 0.000 claims description 17
- 230000001085 cytostatic effect Effects 0.000 claims description 17
- 229920001661 Chitosan Polymers 0.000 claims description 16
- 201000009030 Carcinoma Diseases 0.000 claims description 15
- 239000000824 cytostatic agent Substances 0.000 claims description 15
- 102000008186 Collagen Human genes 0.000 claims description 14
- 108010035532 Collagen Proteins 0.000 claims description 14
- 229920001436 collagen Polymers 0.000 claims description 14
- 229920000954 Polyglycolide Polymers 0.000 claims description 12
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 12
- 239000004753 textile Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000004814 polyurethane Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 239000002674 ointment Substances 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 229920001296 polysiloxane Polymers 0.000 claims description 9
- 229920002635 polyurethane Polymers 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 8
- 229920001610 polycaprolactone Polymers 0.000 claims description 8
- 229920000728 polyester Polymers 0.000 claims description 8
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 7
- 150000002009 diols Chemical class 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 229920002492 poly(sulfone) Polymers 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 229920002943 EPDM rubber Polymers 0.000 claims description 6
- 229930192392 Mitomycin Natural products 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 6
- 229920000297 Rayon Polymers 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 6
- 239000002964 rayon Substances 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 229920001710 Polyorthoester Polymers 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 230000001028 anti-proliverative effect Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 238000009792 diffusion process Methods 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 5
- 229920001220 nitrocellulos Polymers 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 229920002647 polyamide Polymers 0.000 claims description 5
- 239000004632 polycaprolactone Substances 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- 229920001291 polyvinyl halide Polymers 0.000 claims description 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 4
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 102000015790 Asparaginase Human genes 0.000 claims description 4
- 108010024976 Asparaginase Proteins 0.000 claims description 4
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 239000004695 Polyether sulfone Substances 0.000 claims description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 4
- 206010046431 Urethral cancer Diseases 0.000 claims description 4
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
- 229920002494 Zein Polymers 0.000 claims description 4
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- 229960001220 amsacrine Drugs 0.000 claims description 4
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229960003272 asparaginase Drugs 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229960000640 dactinomycin Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229960001428 mercaptopurine Drugs 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 4
- 229960002340 pentostatin Drugs 0.000 claims description 4
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 4
- 229920006393 polyether sulfone Polymers 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 229960004964 temozolomide Drugs 0.000 claims description 4
- 229960001278 teniposide Drugs 0.000 claims description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 4
- 229960003087 tioguanine Drugs 0.000 claims description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 4
- 229960001727 tretinoin Drugs 0.000 claims description 4
- 229960003048 vinblastine Drugs 0.000 claims description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- 229960004355 vindesine Drugs 0.000 claims description 4
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 4
- 239000005019 zein Substances 0.000 claims description 4
- 229940093612 zein Drugs 0.000 claims description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 3
- 229920002284 Cellulose triacetate Chemical class 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- 229920002971 Heparan sulfate Polymers 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
- 108010000817 Leuprolide Proteins 0.000 claims description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 229920002614 Polyether block amide Polymers 0.000 claims description 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 3
- 239000004642 Polyimide Substances 0.000 claims description 3
- 229920002367 Polyisobutene Polymers 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 3
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 claims description 3
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 claims description 3
- 229960003437 aminoglutethimide Drugs 0.000 claims description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 3
- 229960002932 anastrozole Drugs 0.000 claims description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000002429 anti-coagulating effect Effects 0.000 claims description 3
- 230000002095 anti-migrative effect Effects 0.000 claims description 3
- 230000002785 anti-thrombosis Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 229960002938 bexarotene Drugs 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229960005243 carmustine Drugs 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 3
- 229920001727 cellulose butyrate Polymers 0.000 claims description 3
- 229920003086 cellulose ether Chemical class 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000019065 cervical carcinoma Diseases 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960002436 cladribine Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 229960003901 dacarbazine Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- 229960002086 dextran Drugs 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 239000003822 epoxy resin Substances 0.000 claims description 3
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 3
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 3
- 229960001842 estramustine Drugs 0.000 claims description 3
- 229960000255 exemestane Drugs 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229960000390 fludarabine Drugs 0.000 claims description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229960004421 formestane Drugs 0.000 claims description 3
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 229960000908 idarubicin Drugs 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 229960003881 letrozole Drugs 0.000 claims description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 3
- 229960004338 leuprorelin Drugs 0.000 claims description 3
- 229960002247 lomustine Drugs 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 229960003775 miltefosine Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 229960001420 nimustine Drugs 0.000 claims description 3
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 claims description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000647 polyepoxide Polymers 0.000 claims description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 229920001721 polyimide Polymers 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- 229920006124 polyolefin elastomer Polymers 0.000 claims description 3
- 229920006324 polyoxymethylene Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 229920006216 polyvinyl aromatic Polymers 0.000 claims description 3
- 229920001290 polyvinyl ester Polymers 0.000 claims description 3
- 229920001289 polyvinyl ether Polymers 0.000 claims description 3
- 229920006215 polyvinyl ketone Polymers 0.000 claims description 3
- 229920006214 polyvinylidene halide Polymers 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 229960001196 thiotepa Drugs 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- 229960003181 treosulfan Drugs 0.000 claims description 3
- 229960004824 triptorelin Drugs 0.000 claims description 3
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 3
- 229960000875 trofosfamide Drugs 0.000 claims description 3
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims description 3
- JPMICTZIAZZHCD-AKGZTFGVSA-N (2s)-2-amino-4-ethylpentanedioic acid Chemical compound CCC(C(O)=O)C[C@H](N)C(O)=O JPMICTZIAZZHCD-AKGZTFGVSA-N 0.000 claims description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 2
- ZNLAHAOCFKBYRH-UHFFFAOYSA-N 1,4-dioxane-2,3-dione Chemical compound O=C1OCCOC1=O ZNLAHAOCFKBYRH-UHFFFAOYSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- KHEDIYCQDPMFKF-UHFFFAOYSA-N 2-(sulfooxy)acetic acid Chemical compound OC(=O)COS(O)(=O)=O KHEDIYCQDPMFKF-UHFFFAOYSA-N 0.000 claims description 2
- YKVIWISPFDZYOW-UHFFFAOYSA-N 6-Decanolide Chemical compound CCCCC1CCCCC(=O)O1 YKVIWISPFDZYOW-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 229930185605 Bisphenol Natural products 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000009738 Connective Tissue Neoplasms Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 208000009129 Ear Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
- 208000021309 Germ cell tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 206010059282 Metastases to central nervous system Diseases 0.000 claims description 2
- 206010027457 Metastases to liver Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000000260 Warts Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical class O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 201000007538 anal carcinoma Diseases 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 229940046836 anti-estrogen Drugs 0.000 claims description 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 2
- 239000003886 aromatase inhibitor Substances 0.000 claims description 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 2
- 210000000941 bile Anatomy 0.000 claims description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 208000002458 carcinoid tumor Diseases 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 239000000328 estrogen antagonist Substances 0.000 claims description 2
- 239000004052 folic acid antagonist Substances 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 239000003667 hormone antagonist Substances 0.000 claims description 2
- 229940088013 hycamtin Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000010453 lymph node cancer Diseases 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 230000000394 mitotic effect Effects 0.000 claims description 2
- 208000037830 nasal cancer Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 230000000010 osteolytic effect Effects 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 150000003901 oxalic acid esters Chemical class 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 229920003175 pectinic acid Polymers 0.000 claims description 2
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 2
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 claims description 2
- 229920000205 poly(isobutyl methacrylate) Polymers 0.000 claims description 2
- 229920000141 poly(maleic anhydride) Polymers 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 claims description 2
- 229920002721 polycyanoacrylate Polymers 0.000 claims description 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000010153 skin papilloma Diseases 0.000 claims description 2
- 208000014680 small intestine neoplasm Diseases 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 229960005353 testolactone Drugs 0.000 claims description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims description 2
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000023747 urothelial carcinoma Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 229940070710 valerate Drugs 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010062038 Lip neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 230000001741 anti-phlogistic effect Effects 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims 1
- 229920001971 elastomer Polymers 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000006721 lip cancer Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229910001092 metal group alloy Inorganic materials 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 239000005060 rubber Substances 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 229940127554 medical product Drugs 0.000 abstract description 9
- 238000001356 surgical procedure Methods 0.000 abstract description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 34
- 239000000725 suspension Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 210000000988 bone and bone Anatomy 0.000 description 24
- 239000004480 active ingredient Substances 0.000 description 21
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 238000009835 boiling Methods 0.000 description 13
- 235000013980 iron oxide Nutrition 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 238000002513 implantation Methods 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 7
- 108010019393 Fibrin Foam Proteins 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 6
- 229920002201 Oxidized cellulose Polymers 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 102000018146 globin Human genes 0.000 description 5
- 108060003196 globin Proteins 0.000 description 5
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 5
- 239000000696 magnetic material Substances 0.000 description 5
- 229960004857 mitomycin Drugs 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229940107304 oxidized cellulose Drugs 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- 238000005273 aeration Methods 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000012792 core layer Substances 0.000 description 4
- 238000007598 dipping method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 229920002689 polyvinyl acetate Polymers 0.000 description 4
- 239000011118 polyvinyl acetate Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000000015 thermotherapy Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000006065 biodegradation reaction Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920005789 ACRONAL® acrylic binder Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229910000608 Fe(NO3)3.9H2O Inorganic materials 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920000491 Polyphenylsulfone Polymers 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 229910001566 austenite Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229940045110 chitosan Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 238000011254 conventional chemotherapy Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- TVFJAZCVMOXQRK-UHFFFAOYSA-N ethenyl 7,7-dimethyloctanoate Chemical compound CC(C)(C)CCCCCC(=O)OC=C TVFJAZCVMOXQRK-UHFFFAOYSA-N 0.000 description 2
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 125000000879 imine group Chemical group 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229920006027 ternary co-polymer Polymers 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- OZCMOJQQLBXBKI-UHFFFAOYSA-N 1-ethenoxy-2-methylpropane Chemical compound CC(C)COC=C OZCMOJQQLBXBKI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- CRWNQZTZTZWPOF-UHFFFAOYSA-N 2-methyl-4-phenylpyridine Chemical compound C1=NC(C)=CC(C=2C=CC=CC=2)=C1 CRWNQZTZTZWPOF-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YYPNJNDODFVZLE-UHFFFAOYSA-N 3-methylbut-2-enoic acid Chemical compound CC(C)=CC(O)=O YYPNJNDODFVZLE-UHFFFAOYSA-N 0.000 description 1
- AUNDWZCDAOTGDQ-UHFFFAOYSA-N 4-triethoxysilylbutanal Chemical compound CCO[Si](OCC)(OCC)CCCC=O AUNDWZCDAOTGDQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- RNIHAPSVIGPAFF-UHFFFAOYSA-N Acrylamide-acrylic acid resin Chemical compound NC(=O)C=C.OC(=O)C=C RNIHAPSVIGPAFF-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 241000759909 Camptotheca Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229910002441 CoNi Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000004413 Eyelid Neoplasms Diseases 0.000 description 1
- 206010050497 Eyelid tumour Diseases 0.000 description 1
- 229910002555 FeNi Inorganic materials 0.000 description 1
- 229910015189 FeOx Inorganic materials 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000017177 Fibromodulin Human genes 0.000 description 1
- 108010013996 Fibromodulin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 229910001030 Iron–nickel alloy Inorganic materials 0.000 description 1
- 241001125831 Istiophoridae Species 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 108020004422 Riboswitch Proteins 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 229920004935 Trevira® Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- TYVWBCMQECJNSK-UHFFFAOYSA-N [2-methyl-3-(2-methylprop-2-enoyloxy)butan-2-yl]azanium;chloride Chemical compound [Cl-].CC([NH3+])(C)C(C)OC(=O)C(C)=C TYVWBCMQECJNSK-UHFFFAOYSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000005290 antiferromagnetic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- UTOVMEACOLCUCK-PLNGDYQASA-N butyl maleate Chemical compound CCCCOC(=O)\C=C/C(O)=O UTOVMEACOLCUCK-PLNGDYQASA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- NVIVJPRCKQTWLY-UHFFFAOYSA-N cobalt nickel Chemical compound [Co][Ni][Co] NVIVJPRCKQTWLY-UHFFFAOYSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- YOCUPQPZWBBYIX-UHFFFAOYSA-N copper nickel Chemical compound [Ni].[Cu] YOCUPQPZWBBYIX-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical group CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005293 ferrimagnetic effect Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000000027 hemostyptic effect Effects 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical compound CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000013047 polymeric layer Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- KQYLUTYUZIVHND-UHFFFAOYSA-N tert-butyl 2,2-dimethyloctaneperoxoate Chemical compound CCCCCCC(C)(C)C(=O)OOC(C)(C)C KQYLUTYUZIVHND-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- RRHXZLALVWBDKH-UHFFFAOYSA-M trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CC(=C)C(=O)OCC[N+](C)(C)C RRHXZLALVWBDKH-UHFFFAOYSA-M 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
Definitions
- the present invention relates to nanoparticle-containing implantable products and their use in medicine, in particular for thermotherapeutic post-treatment after surgical removal of tumors and cancerous ulcers.
- tumor cells After surgical removal of tumor tissue, there is almost always the problem that tumor cells remain in the body (incomplete resection). After sealing the wound, these tumor cells can grow back into a larger tumor and / or metastasize. For this reason, the chemotherapeutic after-treatment, which is very stressful for the patient, takes place. However, since as little as possible healthy tissue is to be removed, the surgeon must achieve a compromise between as complete as possible tumor removal and the least possible removal of healthy tissue.
- the object of the present invention is to provide products and methods for a more effective post-treatment after cancer surgery.
- implantable medical devices containing nanoparticles which can be heated in the alternating magnetic field enable a significantly improved after-treatment in cancer operations compared to chemotherapy when these medical devices are implanted or introduced into the surgical area.
- the present invention thus relates to a solid or gel-like medical product which can be heated by an alternating magnetic field, wherein the medical device is in the form of a physiologically compatible tissue, sponge, film or gel and wherein magnetic particles are contained in the medical product which are excited by an alternating magnetic field generate and thereby heat the medical device.
- MFH-P02366WO06 Registration Decisive in the case of the medical device according to the invention is that the particles, ie the particles excitable in the alternating magnetic field, are stored or adhered to the medical device in a stationary manner.
- aqueous solutions of magnetic particles are prepared to either direct the particles loaded with pharmacologically active ingredients through a static magnetic field to a specific site of action or aqueous solutions of excitable in the magnetic alternating field particles are injected directly into a tumor, so that the particles in the Enrich tumor cells and destroy the tumor cells by generating heat.
- the heat is generated primarily by hysteresis heat losses of the particles.
- the medical devices according to the invention are not aqueous or physiological aqueous solutions or suspensions of the magnetic particles, but solid or gelatinous carriers such as e.g. a fabric or film in which the particles are firmly embedded. If they are not biodegradable medical devices, the particles remain permanently in the medical device and after implantation, the medical device remains permanently at the implanted position, similar to a dental implant or artificial knee joint.
- the area where the implanted medical device is located may still be at any time, i. after one week after implantation, after one month after implantation, after one year after implantation, and after 10 years after implantation.
- Preferred embodiments of the present invention relate to biodegradable medical devices, which can be degraded at different rates in the human and animal body depending on the indication. From these
- the medical devices of the present invention are in the form of tissues which can be applied to tissue or organs or the surgical site and easily follow the uneven surfaces or in the form of a gel, film-forming composition or film-forming spray which naturally will be applied to any uneven surface to let.
- the operating region is to be understood as that region which is delimited by the outer edges of an operation wound. Described differently, the surgical site is the transition region or interface of tumor tissue to healthy tissue. Treatment or follow-up of this area is very important to prevent recurrence.
- the medical devices described herein are applied to the surgical area, applied and, in the case of a spray, sprayed on the surgical area and are thus intended for postoperative treatment of the surgical wound after tumor surgery.
- the medical devices according to the invention are thus primarily not intended for systemic use, but rather for implantation in the surgical field. Since the medical devices according to the invention should generally preferably remain in the operating area for the duration of the subsequent chemotherapy, the medical devices according to the invention are biodegradable depending on the time interval of planned therapy sessions, bioresorbable or non-degradable over a longer period of time.
- biodegradable or slow biodegradable medical devices preferably have no rigid shape, but can flexibly adapt to the surface of the surgical area to be covered.
- particularly flexible, easily deformable, easily adaptable to other shapes or informal medical devices or carriers for the heatable or heatable particles are preferred.
- the medical devices according to the invention are therefore all non-rigid and non-metallic carriers, which adapt to a given surface and cover it as far as possible and are also suitable for receiving magnetic particles, in particular superparamagnetic nanoparticles.
- the preferably biodegradable medical products according to the invention are medical pulp, dressing materials, wound inserts, surgical
- the medical pulp and the medical textiles preferably represent two-dimensional structures with a small thickness, which are impregnated with the particles.
- the magnetic particles attach to the fibrous structures of this medical device, which in dry or premoistened form is then placed in the wound over the surgical site after surgery.
- Another form of medical device according to the invention are sponges or generally biodegradable porous three-dimensional structures, which may contain the magnetic particles both on the surface and in the interior of the porous structure in the cavities as well as the sponge material itself.
- These sponges are placed in the wound after surgery and fill the operating room largely or even partially. From these spongy structures, the magnetic particles can be released, but the particles can also be present in tightly bound form. The release can be effected both by diffusion of only loosely bound particles from the cavities of the porous structure and by biodegradation of the sponge structure, if the particles are incorporated or incorporated in the material of the sponge structure itself.
- the medical devices according to the invention are intended for implantation in the human and animal body and must therefore be physiologically compatible. It is important that the medical devices of the invention are not present in liquid form as a solution or suspension, but in a formulation which is viscous or viscous or film-forming or solid, so that the medical device after implantation also remains at the desired location.
- a carrier having the magnetic particles
- carrier are the tissues, pulps, gels, film-forming compositions, etc., described in detail herein which may be biodegradable or biostable and are non-magnetic and therefore without the magnetic particles can not be heated in an alternating magnetic field.
- the carriers are not made of living matter
- X-ray marks or contrast agents preferably contain and bind the particles
- the particles are usually not biodegradable, release heat when excited by a magnetic alternating field and thereby heat not only themselves, but also the carrier, so the entire medical device and thus the surrounding tissue.
- pharmacologically active substances such as cytostatics, which can be released by diffusion and / or biodegradation of the carrier and / or heat generation and / or the alternating magnetic field in order, above all, to combat tumor cells .
- tissue refers to any medically used textile or pulp from which dressing materials, dressings, dressings, or other medical wipes or fabrics are made.
- biodegradable medical device refers expressly only to the matrix for the magnetic particles, but not to the magnetic particles themselves, which are not generally biodegradable. Biodegradable are therefore the medical pulp, dressing materials, wound inserts, surgical sutures, compresses, sponges, medical textiles,
- Medical devices with the magnetic particles thus becomes the matrix for the magnetic particles, i. the medical device biodegrades without the magnetic particles and the magnetic particles usually remain or accumulate in the tumor tissue or in the cancer cells and are usually not biodegraded or only a part of their coating is biodegraded, wherein the magnetic core in the Usually not biodegradable.
- the operating room is understood to be the area where the removed tumor or the removed cancerous tissue was located.
- liquid or gel formulations in the form of ointments, creams, gels and sprays, in particular film-forming sprays. These formulations contain the magnetic particles and are applied or sprayed onto the surgical area after removal of the tumor.
- the medical devices according to the invention are preferably biodegradable and therefore preferably dissolve
- the mode of operation of the medical devices according to the invention is that they should cover the surgical area as completely as possible so that the magnetic particles come as close as possible to the remaining cancer cells or remaining cancerous tissue.
- the magnetic particles and preferably superparamagnetic particles can be heated in an alternating magnetic field, which can be by thermotherapy to kill the remaining cancer cells.
- the magnetic particles contained in the medical device according to the invention heat the medical device as a whole and the magnetic particles diffused out of the medical device heat the cancer cells to which they attach or into which they penetrate.
- thermotherapeutic treatment can also support conventional chemotherapy or radiation therapy because the thermotherapeutic treatment causes comparatively few side effects and can be carried out simultaneously with a chemotherapeutic treatment. Since the medical products according to the invention cover the surgical area as completely as possible or should completely fill the operating room, the medical devices according to the invention have the most direct possible contact with the still remaining cancer cells and remaining cancerous tissue, which can be particularly effectively killed by the immediate proximity of the magnetic particles.
- the thermotherapeutic treatment by means of the inventive medicine products is therefore much more selective and gentle than chemotherapy and radiation therapy.
- At least one pharmacologically active substance is bound to said magnetic particles.
- suitable anti-cancer agents are: actinomycins, aminoglutethimide, amsacrine, anastrozole, antagonists of purine and pyrimidine bases, anthracyclines, aromatase inhibitors, asparaginase, anti-estrogens, bexarotene, bleomycin, buselerin, busulfan, camptothecin derivatives, capecitabine, carboplatin, carmustine, chlorambucil , Cisplatin, cladribine, cyclophosphamide, cytarabine (cytosine arabinoside), alkylating cytostatics, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin (adriamycin), epirubicin, estramustine,
- the detachment of at least one therapeutically active substance from the particles can also be effected or initiated by an alternating magnetic field.
- thermotherapeutic treatment is still supported by an antiproliferative active substance directly in the surgical area, which again increases the effectiveness.
- an antiproliferative active substance directly in the surgical area, which again increases the effectiveness.
- a simultaneous or delayed additional chemotherapy or radiotherapy is also possible here.
- the at least one pharmacological active ingredient does not necessarily have to be bound to the particles, preferably nanoparticles. It can additionally be contained in the medical device according to the invention or applied to its surface without being attached to the particles.
- the binding of the active ingredient to the particles has the advantage that a more targeted release takes place, since the active ingredient can penetrate into cancer cells together with the particle or is attached to cancer cells and can be released there initiated by a magnetic field.
- alternating magnetic field means that the magnetic alternating field or the impulses directly cause the release or detachment or indirectly, for example via the activation of enzymes or the generation of heat, a detachment of the active ingredient.
- the nanoparticle-containing medical products in the form of medical pulp, dressing materials, wound inserts, surgical sutures, compresses, medical sponges, medical textiles, ointments, gels or film-forming sprays can thus contain at least one pharmacologically active substance, preferably at least one anticancer agent. Suitable active ingredients and their attachment to the particles are described in detail below.
- the particles are heated in an alternating alternating magnetic field, the strength of the alternating magnetic field preferably being between 1 and 25 kA / m, more preferably between 2 and 18 kA / m and the frequency preferably between 5 and 5000 kHz, more preferably between 10 and 1000 kHz lie.
- the magnetic particles are preferably released superparamagnetic nanoparticles and the optional active ingredients, which attach to cancer cells and kill them.
- This gentle therapy form of thermothermia which has just been described, can be used in particular in combination with other treatment methods such as radiotherapy and / or chemotherapy.
- any magnetic particles can be used, as long as they can be heated by a magnetic alternating field.
- microparticles and in particular nanoparticles and in particular superparamagnetic microparticles and nanoparticles are preferred.
- the nanoparticles mentioned preferably have a magnetic, particularly preferably a superparamagnetic core.
- Preferred are materials such as maghemite, magnetite, iron-nickel alloys, nickel-copper alloys or cobalt-nickel alloys such as FeNi or CoNi.
- a second magnetic core layer may also be attached.
- the result is a higher total coercitive field compared to single-layered nanoparticles.
- the first core layer may be made of superparamagnetic material and the second core layer may be of a material different from the first core layer. Additional layers, which for example also carry active ingredients, can be attached to this core. Multishell particles for introducing particle-drug conjugates into tumor cells are described in the application WO 98/58673 A.
- the core or cores themselves consist of a magnetic material, preferably a ferromagnetic, antiferromagnetic, ferrimagnetic, antiferri magnetic or superparamagnetic material, more preferably iron oxides, in particular superparamagnetic iron oxides or pure iron, which is provided with an oxide layer.
- a magnetic material preferably a ferromagnetic, antiferromagnetic, ferrimagnetic, antiferri magnetic or superparamagnetic material, more preferably iron oxides, in particular superparamagnetic iron oxides or pure iron, which is provided with an oxide layer.
- Such nanoparticles can be heated by an alternating magnetic field with a preferred magnetic field strength between 2 and 25 kA / m and a frequency which is preferably between 5 and 5000 kHz. With this technique, a heating of the tissue containing the nanoparticles to over 50 0 C is possible.
- Such high temperatures can be achieved because up to 800 pg and more iron in the form of nanoparticles per tumor cell can be recorded and so the nanoparticles can not leave the target region over a longer period of time and in this way very precise and contactless from the outside, also repeated Heat can be deposited in the tumor.
- the heating is due to the release of translational and rotational heat as a result of magnetic relaxation processes as well as hysteresis heat losses.
- the nanoparticles preferably consist of iron oxides and in particular of magnetite (Fe 3 O 4 ), maghemite ( ⁇ -Fe 2 O 3 ) or mixtures of these two oxides.
- the preferred nanoparticles can be represented by the formula FeOx wherein X is a rational number from 1 to 2.
- the nanoparticles preferably have a diameter of less than 500 nm.
- the nanoparticles preferably have an average diameter of 15 nm or are preferably in the size range from 1 to 200 nm and particularly preferably in the range from 5 to 30 nm.
- nanoparticles with another than an iron oxide metal core.
- the nanoparticles from a non-magnetic material, such as silicon dioxide (SiO 2 ). Also suitable are silica or polymer particles in which magnetic materials such as the abovementioned magnetic materials are incorporated and / or bonded.
- the magnetic particles may be further derivatized to have chemical structures such as e.g. Antibodies, nucleic acids, peptides, aptamers or other molecules with targeting properties are located on the surface of the particles, which increase the affinity of the particles for degenerate cells. Such surface modifications improve the affinity for cancer cells due to recognition of certain surface structures on the degenerate cells.
- chemical structures such as e.g. Antibodies, nucleic acids, peptides, aptamers or other molecules with targeting properties are located on the surface of the particles, which increase the affinity of the particles for degenerate cells.
- Such surface modifications improve the affinity for cancer cells due to recognition of certain surface structures on the degenerate cells.
- Preferred chemical structures which impart targeting properties to the magnetic particles are, for example, polyclonal antibodies, monoclonal antibodies, humanized antibodies, human antibodies, chimeric antibodies, recombinant antibodies, bispecific antibodies, antibody fragments, aptamers, Fab fragments, Fc fragments, peptides, peptidomimetics, gap mers, ribozymes, CpG oligomers, DNA zyme, riboswitches and lipids.
- therapeutically active substances may optionally be bound to the nanoparticles.
- the binding of the active ingredient can be covalent or by a predominantly covalent bond and / or by a sufficiently strong ionic bond, intercalation compound or complex binding, so that an uncontrolled release of the active ingredient largely disappears.
- An uncontrolled release is the release of the active ingredient without the action of an alternating magnetic field.
- anti-proliferative, anti-migratory, anti-angiogenic, anti-thrombotic, anti-inflammatory, anti-inflammatory, cytostatic, cytotoxic, anti-coagulative, anti-bacterial, anti-viral and / or anti-mycotic active substances it is possible to choose anti-proliferative, anti-migratory, anti-angiogenic, anti-thrombotic, anti-inflammatory, anti-inflammatory, cytostatic, cytotoxic, anti-coagulative, anti-bacterial, anti-viral and / or anti-mycotic active substances.
- these substances can also Radiosensitizer
- cytotoxic and / or cytostatic compounds i. Chemical compounds with cytotoxic and / or cytostatic properties may, inter alia
- Alkylating agents antibiotics with cytostatic properties, antimetabolites,
- cytotoxic agents such as asparaginase, tretinoin,
- Alkaloids Alkaloids, podophyllotoxins, taxanes and Miltefosin ® , hormones, immunomodulators, monoclonal antibodies, signal transducers (signal transduction molecules) and
- Cytokines are used.
- alkylating agents examples include chloroethamine, cyclophosphamide, trofosfamide, ifosfamide, melphalan, chlorambucil, busulfan, thiotepa, carmustine, lomustine, dacarbazine, procarbazine, temozolomide, treosulfan, estradominin and nimustine.
- antibiotics with cytostatic properties are daunorubicin, doxorubicin (adriamycin), dactinomycin, mitomycin C, bleomycin, epirubicin (4-epi- adriamycin), idarubicin, mitoxantrone and amsacrine.
- Methotrexate 5-fluorouracil, 6-thioguanine, 6-mercaptopurine, fludarabine, cladribine, pentostatin, gemcitabine, azathioprine, raltitrexed, capecitabine, cytosine arabinoside, thioguanine and mercaptopurine may be cited as examples of antimetabolites (antimetabolic agents).
- the class of alkaloids and podophyllotoxins include, but are not limited to, vincristine, vinblastine, vindesine, etoposide, and teniposide.
- platinum-containing compounds can be used according to the invention. Examples of platinum-containing compounds are cisplatin, carboplatin and oxaliplatin.
- To the microtubule inhibitors include, for example alkaloids, such as vinca alkaloids (vincristine, vinblastine, vindesine, Venorelbin) and taxanes (paclitaxel / Taxol ®, paclitaxel and docetaxel), as well as derivatives of paclitaxel.
- topoisomerase inhibitors include podophyllotoxins (etoposide, teniposide) and camptotheca alkaloids (camptothecin, topotecan and irinotecan).
- cytostatic agents include, for example hydroxycarbamide (hydroxyurea), imatinib, miltefosine ®, amsacrine,
- Compound class of the monoclonal antibodies include trastuzumab (Herceptin ® also known as), Alemtuzumab (also known as Campath ®) and rituximab (also known as MabThera ®).
- Hormones such as, for example, glucocorticoids (prednisone), estrogens (Fosfestrol, estramustine), LHRH (buserelin, goserelin, leuprorelin, triptorelin), flutamide, cyproterone acetate, tamoxifen, toremifene, aminoglutethimide, formestane, exemestane, letrozole and anastrozole can also be used according to the invention.
- prednisone prednisone
- estrogens Frasfestrol, estramustine
- LHRH buserelin, goserelin, leuprorelin, triptorelin
- flutamide cyproterone acetate
- tamoxifen toremifene
- aminoglutethimide aminoglutethimide
- formestane formestane
- letrozole and anastrozole can also be used according to the invention.
- cytokines cytokines, antibodies and signal counted interleukin-2, interferon- ⁇ , interferon- ⁇ , erythropoietin, G- CSF, trastuzumab (Herceptin ®), rituximab (Mabthera ®), Efitinib (Iressa ®), Ibritumomab ( Zevalin ®), levamisole and retinoids.
- the aforementioned active ingredients may be contained together with the magnetic particles in the medical device according to the invention or applied to the surface thereof.
- the attachment of the drug takes place, for example, via hydroxyl groups, amino groups, carbonyl groups, thiol groups or carboxyl groups, whichever functional Groups of the respective active ingredient contributes.
- Hydroxy groups are preferably bonded as ester, acetal or ketal, thio groups preferably as thioester, thioacetal or thioketal, amino groups preferably as amides and partly also as imines (Schiff bases), carboxyl groups preferably as esters or amides and carbonyl groups preferably as ketals.
- the active substance or substances directly to a nanoparticle or the medical device or the biodegradable medical device, but rather to immobilize it via a linker molecule.
- the functionalization of the surface of the nanoparticles is known, so that amino groups, hydroxyl groups, carboxyl groups or carbonyl groups can be produced on the surface of the nanoparticles by known methods.
- the therapeutically active substances are directly or via a linker molecule, preferably by means of an amide bond or ester bond to the nanoparticles
- linkers which contain pH-cleavable acetal, ester, hydrazone or imine groups and can be cleaved acidically or by enzymatic reaction.
- the enzymatically cleavable group in or on the linker molecule is the amide group.
- Thermally or acid cleavable groups include e.g. Phosphate groups, thiophosphate groups, sulfate groups, phosphamide groups, carbamate groups or imine groups.
- the active ingredient need not necessarily be covalently bound to the linker or the bioresorbable medical device, but may also be ionic or hydrogen bonded or intercalated or complexed.
- any magnetic particles can be used in the medical devices according to the invention.
- Examples of such magnetic particles are described in WO 2005070471 A2, WO 0243708 A2, US Pat. No. 5,411,730 A1, WO 2005042142 A2, WO 03026618 A1, WO 2005065282 A2, WO 2006108405 A2 and WO 2007019845 A2.
- Biodegradable Medical Devices The biodegradable medical devices of the present invention, in the form of implants, gels, tissues, textiles, dressings or film-forming compositions, remain in the patient's body following closure of the wound following cancer surgery by the surgeon.
- biodegradable medical products according to the invention are used, in particular, for the after-treatment of the surgical area with heat generated by means of thermotherapy for the purpose of killing remaining tumor cells and for preventing recurrence formation.
- biodegradable medical devices of the invention consist of physiologically acceptable materials and / or are cleaved into physiologically acceptable degradation products and components.
- the materials for the medical devices according to the invention are selected from the group comprising or consisting of: polyacrylic acid, polyacrylates, polymethyl methacrylate, polybutyl methacrylate, polyisobutyl methacrylate, polyacrylamide, polyacrylonitrile, polyamide, polyether amide, polyethyleneamine, polyimide, polycarbonate, polycarbourethane, polyvinyl ketone, polyvinyl halide, polyvinylidene halide, Polyvinyl ethers, polyvinyl aromatics, polyvinyl esters, polyvinyl pyrollidone,
- Polyoxymethylene Polyethylene, polypropylene, polytetrafluoroethylene, polyurethane, polyolefin elastomer, polyisobutylene, EPDM rubbers, fluorosilicone,
- Carboxymethyl chitosan polyethylene terephthalate, polyvalerate, carboxymethyl cellulose, cellulose, rayon, rayon triacetate, cellulose nitrate, cellulose acetate, hydroxyethyl cellulose, cellulose butyrate, cellulose acetate butyrate, ethylvinyl acetate copolymer, polysulfone, polyethersulfone, epoxy resin, ABS resins, EPDM rubbers, silicone prepolymer, silicone, polysiloxane, Polyvinyl halides, cellulose ethers, cellulose triacetate, chitosan, chitosan derivatives, polymerizable oils, polyvalerolactones, poly- ⁇ -decalactone, polylactide, polyglycolide, copolymers of polylactides and polyglycolides, poly- ⁇ -caprolactone, polyhydroxybutyric acid, polyhydroxybutyrate, polyhydroxyvalerate, polyhydroxybutyrate-co-valerate
- the aforementioned polymers are biodegradable or can be prepared in degrees of polymerization and degrees of crosslinking which are biodegradable.
- biodegradable or “bioabsorbable” is understood to mean that these materials are degraded or degraded to over 90% by weight under physiological conditions within a period of 1 month to 12 months, preferably up to 6 months.
- Preferred biodegradable polymers are polylactides, polyglycolides, copolymers of polylactides and polyglycolides, polyhydroxybutyrates, polyhydroxymethacrylates, polyorthoesters, glycolated polyesters, polyvinyl alcohols, polyvinylpyrrolidone, acrylamide-acrylic acid copolymers, hyaluronic acid, heparan sulfate, heparin, chondroitin sulfate, dextran, ⁇ -cyclodextrins, hydrophilic crosslinked dextrins , Alginates, phospholipids, carbomers, crosslinked peptides and proteins, silicones, polyethylene glycol (PEG), polypropylene glycol (PPG), copolymers of PEG and PPG, collagen, polymerizable oils and waxes, such as their mixtures and copolymers.
- PEG polyethylene glycol
- PPG polypropylene glycol
- polyesters, polylactides and copolymers of diols and esters or diols and lactides are preferred.
- Ethane-1, 2-diol, propane-1, 3-diol or butane-1, 4-diol are used as diols, for example.
- polyesters for the polymeric layer are used according to the invention. From the group of polyesters, in turn, those polymers are preferred which have the following repeating unit:
- R, R 1 , R "and R"' represent an alkyl radical having 1 to 5 carbon atoms, in particular methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, t-butyl, iso-butyl, n -Pentyl or cyclopentyl and preferably methyl or ethyl.
- Y is an integer from 1 to 9 and X is the degree of polymerization. Particular preference is given to the following polymers having the repeating units shown:
- resorbable polymers are particularly preferred in the present invention. Also preferred are homopolymers of lactic acid (polylactides) and polymers made from lactic and glycolic acids.
- biostable or non-biodegradable medical devices of the invention in the form of gels, sponges, and especially film-forming compositions, film-forming sprays or textiles, fabrics, pulp, wound dressings, and the like, are made of non-biodegradable or hardly degradable materials.
- the materials for the biostable medical devices according to the invention are selected from the group consisting of or consisting of: polyacrylic acid and
- Polyacrylates such as polymethylmethacrylate, polybutylmethacrylate, polyacrylamide, polyacrylonitriles, polyamides, polyetheramides, polyethyleneamine, polyimides,
- Preferred biostable polymers used in medical technology and for biostable implants are polyethersulfone, substituted polyethersulfone, polyphenylsulfone, substituted polyphenylsulfone, polysulfone block copolymers, perfluorinated polysulfone block copolymers, semifluorinated polysulfone block copolymers, substituted polysulfone block copolymers and / or mixtures of the aforementioned polymers.
- the nanoparticles according to the invention can also be introduced into gels or hydrogels or be constituents of film-forming sprays, which are preferably also biodegradable.
- the nanoparticles according to the invention described herein can be combined with gel or film formers.
- Suitable gelling agents or film formers are preferably cellulose-based substances such as cellulose nitrate or ethylcellulose or physiologically acceptable polymers thereof, polyvinyl acetate, partially saponified polyvinyl acetate, copolymers of vinyl acetate and acrylic acid or crotonic acid or maleic monoalkyl esters, ternary copolymers of vinyl acetate and crotonic acid and vinyl neodecanoate, or crotonic acid and vinyl propionate, copolymers of methyl vinyl ether and monoalkyl maleate, in particular as monobutyl maleate, copolymers of fatty acid vinyl and acrylic acid or methacrylic acid, copolymers of N-vinylpyrrolidone, methacrylic acid and methacrylic acid, copolymers of acrylic acid and methacrylic acid or alkyl acrylate or alkyl methacrylate, in particular containing quaternary ammonium groups , or polymers, copoly
- MFH-P02366WO06 Registration Mixtures comprising ethyl acrylate, methyl methacrylate or Trimethylammonio- ethyl methacrylate chloride, or polyvinylacetals and polyvinylbutyrals, alkyl-substituted poly-N-vinylpyrrolidones, alkyl esters from copolymers of olefins and maleic anhydride, reaction products of colophony with acrylic acid and Benzoeharze, chitosan, Luvimer 100 ®, Alumniumstearat , Carbomers, cocamide MEA, carboxymethyldextran, carboxymethylhydroxypropyl guar or red algae carrageenans.
- the alkyl radicals are usually short chain and usually have not more than four C atoms.
- Such substances are also referred to herein as polymer-forming or gel-forming substances.
- Water-soluble polymers such as, for example, ionic polyamides, polyurethanes and polyesters, as well as homopolymers and copolymers of ethylenically unsaturated monomers, also belong to the gelling agents or film formers.
- Such materials are, for example, under the trade names Acronal ®, Acudyne ®, Amerhold ®, Amphome ®, Eastman AQ ®, Ladival ®, Lovocryl ®, Luviflex VBM ®, Luvimer ®, Luviset PU R ®, Luviskol ®, Luviskol ® Plus, Stepanhold ® , Ultrahold ® , Ultrahold Strang ® or Versatyl ® .
- Luvimer ® is a polyacrylate.
- gels according to the invention may be, above all, natural polymers. These include albumin, collagen, hyaluronan, chitosan and chitin.
- a particularly preferred non-natural polymer is copolymer or block copolymer of polyethylene oxide with terminal ⁇ -hydroxy acids or poly- ⁇ -hydroxy acids.
- glycosaminoglycans such as aggrecan, decorin, biglycan and fibromodulin are common constituents of bioresorbable gels or film-forming solutions or sprays.
- Saline solutions such as physiological (0.9%) saline, PBS (phosphate buffered saline) DMEM (Dulbecco's Modified Eagle Medium) can also be used in the gels, solutions and sprays.
- physiological (0.9%) saline, PBS (phosphate buffered saline) DMEM (Dulbecco's Modified Eagle Medium) can also be used in the gels, solutions and sprays.
- a proportion of 3-30% by weight of iron oxide on 200 mg of gel is preferred, more preferably a proportion of 5-25% by weight of iron oxide on 200 mg of gel, and particularly preferably one Proportion of 10-20% by weight of iron oxide to 200 mg of gel.
- the magnetic particles may already be added during the production of polymers and then incorporated into the bioresorbable polymeric structure.
- biodegradable medical devices are polymeric beads containing the magnetic particles.
- the polymer beads preferably consist of polyhydroxybutyrate, polylactide, polyglycolide or copolymers of polylactide-co-glycolide.
- Another particularly preferred material is alginate and Eudragit ®. These polymer beads contain up to 20% by weight of magnetic particles.
- the polymer beads can be used as such or incorporated into gels or pastes or immobilized on medical pulp.
- the polymer beads can be heated in alternating magnetic field up to temperatures of 50 0 C.
- coated medical implantable products to which the nanoparticles are applied are preferably bioabsorbable. That is, they can completely dissolve in the body or are at least physiologically well tolerated.
- the medical implants containing nanoparticles include, but are not limited to, medical pulp, dressings, wound inserts, surgical sutures, compresses, and medical textiles.
- Polyhydroxybutyrates and cellulose derivatives, chitosan derivatives as well as collagen, polyethylene glycol, polyethylene oxide and polylactides are preferred materials for medical pulps and textiles.
- alginates When alginates are used as the wound dressing, it is preferred to use calcium alginate with sodium carboxymethylcellulose interwoven products.
- the SeaSorb Soft from Coloplast is an example.
- nanoparticles are applied to wound dressings and / or wound inserts, especially the products Tabotamp ® and Spongostan ® the company
- sutures are preferably used, which are preferably polyglycolic acid, polycaprolactone coglycolide, or poly-p-dioxanone. Examples include the products Marlin ® , PCL and Marisorb ® Catgut GmbH called.
- compresses are to be impregnated with the nanoparticles, particularly sterile 100% cotton gauze compresses should be used.
- Examples include the product lines Stericomp ® and Askina ® .
- Trevira ® products are preferred.
- the medical textiles and pulps are sprayed or dipped in a solution of the magnetic particles in water, ethanol or water-ethanol mixtures, wherein the dipping or spraying process can be repeated several times after drying the medical device.
- the medical sponges are bioresorbable implants with a sponge-like, porous structure.
- Preferred materials for the medical sponges are collagen, oxidized cellulose, chitosan, thrombin, fibrin, chitin, alginates, hyaluronic acid, PLGA, PGA, PLA, polysaccharides and globin.
- an ointment base consisting of purified water in an amount of preferably 5-50% by weight, more preferably 10-40% by weight, and most preferably 20-30% by weight.
- the ointment also contains Vaseline in an amount of preferably 40-90% by weight, more preferably 50-80% by weight and most preferably 20-60% by weight.
- the ointment may still contain thick liquid paraffin in an amount of 5-50% by weight, more preferably 10-40% by weight, and most preferably 20-30% by weight.
- the gelling agents and / or film formers mentioned herein may also be added in an amount of up to 30% by weight.
- polymers such as cellulose, chitosan, thrombin, fibrinogen, chitin, alginates, albumin, hyaluronic acid, hyaluronan, polysaccharides, globin, polylactide, polyglycolide, polylactide-co-glycolide, polyhydroxybutyrates, cellulose derivatives, chitosan derivatives, polyethylene glycol and polyethylene oxide in amounts up to 30 wt .-% are used.
- Film-forming sprays The nanoparticles according to the invention can also be introduced into spray solutions or be constituents of film-forming sprays.
- the magnetic particles or active agent-containing nanoparticles described herein can be combined with gel or film formers.
- Film-forming sprays contain at least one or more film formers.
- Suitable film formers are preferably cellulose-based substances such as cellulose nitrate or ethylcellulose or physiologically acceptable polymers thereof, polyvinyl acetate, partially saponified polyvinyl acetate, copolymers of vinyl acetate and acrylic acid or crotonic acid or monoalkyl maleate, ternary copolymers of vinyl acetate and crotonic acid and vinyl neodecanoate, or crotonic acid and vinyl propionate, copolymers of methyl vinyl ether and Maleinklaremonoalkylester, especially as Maleinkladobutylester, copolymers of fatty acid vinyl esters and acrylic acid or methacrylic acid, copolymers of N-vinylpyrrolidone, methacrylic acid and
- Methacrylic acid alkyl esters copolymers of acrylic acid and methacrylic acid
- Trimethylammonioethylmethacrylat chloride or polyvinyl acetals and polyvinyl butyrals, alkyl-substituted poly-N-vinylpyrrolidone, alkyl esters of copolymers of olefins and maleic anhydride, reaction products of rosin with acrylic acid and benzo resins, chitosan, Luvimer 100 ® , Alumniumstearat, carbomers, cocamide MEA, carboxymethyldextran, carboxymethylhydroxypropyl guar or red algae carrageenans.
- the alkyl radicals are usually short chain and usually have not more than four C atoms.
- the film formers also include water-soluble polymers such as ionic polyamides, polyurethanes and polyesters and homo- and copolymers of ethylenically unsaturated monomers.
- water-soluble polymers such as ionic polyamides, polyurethanes and polyesters and homo- and copolymers of ethylenically unsaturated monomers.
- Luvimer ® is a polyacrylate as a hair styling polymer developed by the company
- solvent water, ethanol or water-ethanol mixtures are preferred.
- Proportion of 10-20% by weight of iron oxide to 200 mg of gel most preferred.
- the preparation of the nanoparticle-containing implants by means of dipping or spraying.
- the products to be implanted are immersed in a nanoparticle-containing solution or suspension or sprayed with a solution containing nanoparticles. Thereafter, the products are dried and packaged sterile.
- the gels, ointments, solutions and sprays are obtained by preparing the desired pharmaceutical preparation according to standard methods and preferably adding the desired amount of magnetic particles in a final step.
- the resulting biodegradable medical devices according to the invention are used for the treatment and prophylaxis of tumors, carcinomas and cancers and serve in particular for the after-treatment of the surgical area after a cancer operation and in particular after removal of a solid tumor.
- cancer and tumor types where the medical devices according to the invention can be used are: adenocarcinomas, choroidal melanoma, acute leukemia, acoustic neuroma, ampoule carcinoma, anal carcinoma, astrocytomas, basal cell carcinoma, pancreatic cancer, connective tissue tumor, bladder cancer, bronchial carcinoma, non-small cell lung carcinoma, Breast cancer, Burkitt's lymphoma, corpus carcinoma, CUP syndrome, colon cancer, small bowel cancer, small intestine tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancers, Ewing tumors, gastrointestinal tumors, gall bladder cancer, bile carcinomas, uterine cancer, cervix cancer, glioblastomas, gynecological tumors, cervical cancer , Nose and ear tumors, hematologic neoplasms, urethral cancer, skin cancer, brain tumors (gliomas), brain metastases, test
- Stomach cancer malignant melanoma, malignant neoplasm, malignancies of the gastrointestinal tract, breast cancer, rectal cancer, medulloblastoma, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer, neuroma, neuroblastoma, kidney cancer, renal cell carcinoma, non-Hodgkin's lymphoma, oligodendroglioma, Esophageal carcinoma, osteolytic carcinomas, u.
- osteoplastic carcinoma osteosarcoma
- ovarian carcinoma pancreatic carcinoma
- penile cancer squamous cell carcinoma of the head and neck
- prostate cancer pharyngeal cancer
- rectal carcinoma retinoblastoma
- vaginal cancer vaginal cancer
- Thyroid carcinoma Schneeberger's disease, esophageal cancer, spinal, T-cell lymphoma (Mycosis fungoides), thymoma, tubal carcinoma, tumors of the eye, urethral cancer, urological tumors, urothelial carcinoma, vulvar cancer, wart involvement, soft tissue tumors, soft tissue sarcoma, Wilms tumor, cervical carcinoma and tongue cancer.
- Especially solid tumors are preferred. Also preferred are prostate cancers, brain tumors, sarcomas, cervical carcinomas, ovarian cancers, breast cancers, bronchial carcinomas, melanomas, head and neck tumors,
- MFH-P02366WO06 Registration Esophageal carcinomas, rectal cancers, pancreatic, bladder and renal carcinomas, metastases of the liver, brain and lymph nodes.
- bioresorbable medical products according to the invention in medicine are preferably further preferred together with the radiation therapy and / or together with the conventional chemotherapy.
- thermotherapy involves a localized use of anticancer drugs, thus reducing the burden of medication and the side effects on the patient.
- the likelihood of re-metastasis is greatly reduced, as locally, a cancer treatment of the remaining after an incomplete resection tumor cells selectively takes place.
- the medicaments which may be present on the implant or the medical device according to the invention can also be detached from the nanoparticle by an alternating magnetic field applied from the outside and can more selectively exert their effect directly at the site of action. This also allows for more accurate drug dosing, as the local therapy regimen does not lose any medication during transport through the body.
- the method described above is also effective with nanoparticles without attached drug against cancer cells feasible.
- the nanoparticles attach themselves to the cancer cells or penetrate into the cancer cells and destroy the cancer cells by an externally applied magnetic field, which heats the magnetic particles.
- molecules with targeting properties can be found on the surface of the nanoparticles or on the outer layer or shell of the nanoparticles.
- monoclonal antibodies and / or aptamers can be found on the surface of the nanoparticles or on the outer layer or shell of the nanoparticles.
- the cores of the magnetic nanoparticles consist of magnetite (Fe 3 O 4 ), maghemite ( ⁇ -Fe 2 O 3 ) or mixtures of these two oxides and are preferably superparamagnetic.
- the cores are stabilized by colloidal protective sheaths, which enable a connection of the therapeutically active substances.
- a solution of 0.23 mol of FeCl 2 and 0.46 mol of FeCl 3 in 1 l of water is degassed with nitrogen. Then 5M NaOH is added within 20 minutes to reach a pH of 11.5.
- the resulting precipitate is heated to 65 ° C for 10 minutes and then cooled to room temperature over 5 minutes. Subsequently, the precipitate is suspended with deionized and degassed water until the pH of the washing solution 9 has reached.
- the precipitate is suspended in water and the suspension is adjusted to pH 6 with glacial acetic acid. 10% by volume of a 30% strength by weight aqueous H 2 O solution are added to the resulting suspension, followed by stirring until gas evolution ceases, whereupon the suspension is diluted with water to a solids content of 5% by weight of iron oxide.
- Example 1 B (without oxidation / with air aeration):
- the particles were washed 3 times with a mixture of ethanol / water.
- Example 1C (with oxidation / with air aeration):
- the particles were washed 3 times with a mixture of ethanol / water. Thereafter, the particles were resuspended in 900 ml of ethylene glycol and fumigated with atmospheric oxygen. The suspension was heated to the boiling point of the ethylene glycol and kept at this temperature for 24 hours.
- Example 1 D (without oxidation / without air aeration):
- the particles were washed 3 times with a mixture of ethanol / water.
- Suspension was heated to the boiling point of ethylene glycol and kept at this temperature for 24 hours.
- Example 1 E (with oxidation / without air aeration):
- Diaminohexane dissolved in 900 ml of ethylene glycol and heated to 6O 0 C for 1 hour. Then the solution was heated to the boiling point within 30 minutes.
- Boiling temperature was maintained for 6 hours.
- the resulting dispersion was slowly cooled to room temperature.
- the particles were washed 3 times with a mixture of ethanol / water.
- Iron (III) chloride hexahydrate in 500 ml of methanol. The resulting solid was washed with methanol and dissolved in diethyl ether. Then it was extracted several times with water. The solid was precipitated with acetone, washed and dried in vacuo.
- Dispersion was slowly cooled to room temperature.
- the particles were washed 3 times with a mixture of ethanol / water.
- the particles were suspended in 300 ml of diethylene glycol dibutyl ether and aerated with atmospheric oxygen.
- the suspension was heated in an autoclave to 300 ° C for 24 hours kept at this temperature.
- Example 1 C These particles were oxidized as in Example 1 C and then coated analogously to Example 1G.
- Example 1 B to 1 F The particles from Example 1 B to 1 F were centrifuged off at high g-numbers and washed with ethanol. 500 mg of the washed product were weighed into an extraction sleeve (603g company Whatman) and placed in a Soxhlet apparatus. 200 ml of ethanol as extractant were introduced into the receiver flask of the Soxhlet apparatus. The extractant was heated to boiling. The continuous extraction was carried out for 8 hours and included about 16
- Example 4 To disperse the particles after extraction, 0.5 g of the nanoparticle powder of Example 4 was suspended in 20 ml of 0.01 M HCl. Then, the nanoparticles were sonicated for 30 minutes. Thereafter, 0.5 g of solid sodium oleate was added.
- a commercial Tabotamp ® sponge was immersed for 6 minutes in the prepared in Example 1 nanoparticle suspension. After drying, the dipping process was repeated a further two times. Alternatively, the suspension can be applied with a syringe. This process can be repeated several times until the desired loading of the sponge is achieved.
- a 3 cm wide and 6 cm long piece of a wound dressing such as SeaSorb Soft from Coloplast consisting of calcium alginate and sodium carboxymethyl cellulose was sprayed 5 times with about 1 ml of the nanoparticle suspension according to Example 1 and after each spraying about 20 minutes in the air dried.
- the suspension can be applied with a syringe. This process can be repeated several times until the desired loading of the sponge is achieved.
- MFH-P02366WO06 Registration A commercial medical pulp of sodium carboxymethylcellulose, poly-N-vinylpyrrolidone and polyethylene oxide (5 cm 2 ) was immersed for 5 minutes in a prepared according to Example 1 nanoparticle suspension containing 0.3 mg paclitaxel per ml of solution. After drying and sterilizing, the medical device is ready for use.
- Preparation of a gel according to the invention 4 g of a mixture of collagen type I and collagen type II are dissolved in one liter of a 50 mM acetic acid solution. The collagen solution is centrifuged for 45 minutes at 4 ° C and 9500 revolutions per minute. The supernatant is decanted, filled into a dialysis tube and dialysed against 25 liters of a 1 M acetic acid solution for two days and then dialyzed against water for a further 4 days.
- the collagen solution in the dialysis tube was concentrated to a concentration of 20 mg / ml (2% w / v).
- the gel was applied as completely as possible to the surgical site.
- thermotherapy in the alternating magnetic field showed a heating of the operating areas to 53 ° C.
- Example 6 Gel with Active Ingredient To 10 g of the gel prepared according to example 5 are added 0.1 g of the cytostatic temozolomide and then mixed well.
- a spongy implant is prepared by lyophilizing a 1% aqueous suspension of oxidized cellulose at pH 7.2 with 1.5% by weight globin powder.
- the oxidized cellulose can also be used in the form of fibers or two- or three-dimensional structures.
- the resulting sponge-like structure consists of about 100 mg oxidized cellulose and between 40 and 200 mg globin and has a volume of about 10 cm 3 and a thickness of about 3 mm.
- the spongy structure is sterilized with ethylene oxide and packaged.
- Example 8A Particles with Active Ingredient
- a conjugate of mitomycin and an aldehyde-functionalized alkoxysilane (e.g., triethoxysilylbutyraldehyde) is first synthesized.
- an aldehyde-functionalized alkoxysilane e.g., triethoxysilylbutyraldehyde
- the active ingredient is coupled via an imine bond.
- This conjugate is added with stirring to an aqueous dispersion of aminosilane-stabilized particles, e.g. those given in WO 97/38058 A.
- Ethylene glycol is added to the mixture and the water is removed by distillation.
- the conjugate of active ingredient and silane is coupled (condensed) to the already existing aminosilane-based shell.
- the purification is carried out by dialysis against ultrapure water. A detailed reaction description is contained in WO 2006108405 A2.
- nanoparticles with doxorubicin bound to the particle via an avidin bridge are carried out as described in WO 2006108405 A2.
- Doxorubicin is carried out as described in WO 2006108405 A2.
- a sponge-like structure is prepared as described in Example 7, using instead of oxidized cellulose a mixture of collagen type I, collagen type II and chitosan (25% by weight: 25% by weight: 50% by weight).
- the sponge obtained is impregnated with an aqueous suspension of nanoparticles with coupled doxorubicin according to Example 8B or 8C and dried.
- the nanoparticle suspension according to Example 8A, 8B or 8C can also be added to the suspension according to Example 7 and lyophilized together with the other components.
- Example 10 Medical Pulp Medical pulp based on chitosan, uronic acid and carboxymethyldextran (4 cm 2 about 20 mg) is spread flat in a Petri dish and drizzled with an aqueous suspension containing nanoparticles with coupled mitomycin according to Example 8A until the loading of the pulp is achieved with 50 mg of nanoparticles.
- the resulting gel was stirred with the nanoparticle suspension of Example 1 for 4 h.
- Example 12 Film-forming spray with nanoparticles
- feed 1 diethyl maleate
- feed 2 maleic anhydride
- feed 3 vinyl isobutyl ether
- feed 4 tert-butylper-neodecanoate
- the resulting viscous polymer solution was stirred with the nanoparticle suspension of Example 1 for 2 h.
- Example 13 Film-forming spray with nanoparticles and active ingredient
- Example 14 Treatment of Cervical, Thoracic and Otolaryngeal Tumors
- a carrier material impregnated with a nanoparticle solution according to Example 1A (2 molar & 3 molar) is consumed.
- the bone is positioned in the therapy device and exposed to a magnetic field.
- the temperature increase to be measured on the bone is determined.
- This experimental setup shows that cervical, thoracic and ENT tumors can be treated in the alternating magnetic field by means of nanoparticle-coated carriers, which are applied to one or in the region of a bone.
- Alginate alginic acid sodium salt
- modeling clay serves as marking aid
- ⁇ 3 field strengths (relevant for clinical use) are measured: 3.0 kA / m, 3.5 kA / m, 4.0 kA / m
- % Field strength is the device setting that corresponds to the assigned field strength in kA / m
- the temperature of the air space and the applicator base is determined in the fixator
- Nanopratikelsuspension of Example 1A (0.5 mL, 2 Molar)
- Carrier Lyostypt ®, size: (19,95x14,9x3,4)
- mm bone Size: (44.4 x 13.2 x 10.9) mm
- One bone piece was measured [dimensions: (44.4x13.2x10.9) mm] and one piece of support [dimensions: (19.95x14.9x3.4) mm] was cut to size.
- the carrier is placed on the bone and soaked with the particles (0.5 mL, 2 molar of Example 1A).
- the loaded bone is positioned in the applicator [probe 1 (red): vertically from above on the soaked carrier; Probe 2 (blue): basal value ("empty" bone)] and for the wearer the measured values are determined:
- the probe is always positioned between the carrier and the bone.
- Nanopriate suspension according to Example 1A (1, 5 mL, 2 molar)
- Carrier Spongostan powder, mass: 0.3 g
- Bones Size: (44.4 x 13.2 x 10.9) mm
- plasticine serves as a marking aid.
- Three field strengths (relevant for clinical use) are measured: 3.0 kA / m, 3.5 kA / m, 4.0 kA / m
- Carrier impregnated support from Example 14B, mass: approx. 0.8 g
- Bones Size: (44.4 x 13.2 x 10.9) mm
- Example 14B The amount of impregnated support left in Example 14B of approximately 0.8 g is mixed with 1.6 ml of particles (2 molar according to Example 1A) and applied to the bone cleaned according to Example 14. The probe is placed again between the bone and the wearer. It was again measured at the 3 field strengths (3.0 kA / m, 3.5 kA / m, 4.0 kA / m).
- Particle Nanopriate suspension according to Example 1A (1, 0 mL, 2 molar)
- Carrier soaked carrier from Example 14B, Size: (10.0x10.0x2, 0) mm
- Bones Size: (44.4 x 13.2 x 10.9) mm
- Example 14E Gelita tampon
- Nanopriate suspension according to Example 1A (1, 0 ml, 2 molar)
- Carrier Gelita tampon, size: (1x1x1) cm
- Bones Size: (44.4 x 13.2 x 10.9) mm
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2010136311/15A RU2524644C2 (ru) | 2008-02-11 | 2009-02-11 | Имплантируемые продукты, содержащие наночастицы |
CA2712832A CA2712832C (en) | 2008-02-11 | 2009-02-11 | Implantable products comprising nanoparticles |
DE112009000905T DE112009000905A5 (de) | 2008-02-11 | 2009-02-11 | Implantierbare Nanopartikel-enthaltende Produkte |
ES09711314.6T ES2619509T3 (es) | 2008-02-11 | 2009-02-11 | Productos implantables que contienen nanopartículas |
MX2010008806A MX2010008806A (es) | 2008-02-11 | 2009-02-11 | Productos implantables que comprenden nanoparticulas. |
EP09711314.6A EP2249804B1 (de) | 2008-02-11 | 2009-02-11 | Implantierbare nanopartikel-enthaltende produkte |
JP2010546211A JP5649455B2 (ja) | 2008-02-11 | 2009-02-11 | ナノ粒子を含む移植可能な製品 |
CN2009801043533A CN101938993A (zh) | 2008-02-11 | 2009-02-11 | 包括纳米粒子的植入式产品 |
BRPI0906611A BRPI0906611A8 (pt) | 2008-02-11 | 2009-02-11 | produtos implantáveis compreendendo nanopartículas |
AU2009214533A AU2009214533B2 (en) | 2008-02-11 | 2009-02-11 | Implantable products comprising nanoparticles |
DK09711314.6T DK2249804T3 (en) | 2008-02-11 | 2009-02-11 | IMPLANTABLE PRODUCTS CONTAINING NANOPARTICLES |
US12/864,793 US20110223255A1 (en) | 2008-02-11 | 2009-02-11 | Implantable products comprising nanoparticles |
ZA2010/04935A ZA201004935B (en) | 2008-02-11 | 2010-07-13 | Implantable products comprising nanoparticles |
IL207137A IL207137A (en) | 2008-02-11 | 2010-07-21 | Heatable surgical implant using an alternating magnetic field for use in continuing surgery in cancer treatment |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008008522.7 | 2008-02-11 | ||
DE102008008522A DE102008008522A1 (de) | 2008-02-11 | 2008-02-11 | Implantierbare Nanopartikel-enthaltende Produkte |
US7108408P | 2008-04-11 | 2008-04-11 | |
US61/071,084 | 2008-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009100716A2 true WO2009100716A2 (de) | 2009-08-20 |
WO2009100716A3 WO2009100716A3 (de) | 2010-09-23 |
Family
ID=40847365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2009/000196 WO2009100716A2 (de) | 2008-02-11 | 2009-02-11 | Implantierbare nanopartikel-enthaltende produkte |
Country Status (18)
Country | Link |
---|---|
US (1) | US20110223255A1 (de) |
EP (1) | EP2249804B1 (de) |
JP (1) | JP5649455B2 (de) |
KR (1) | KR101581973B1 (de) |
CN (1) | CN101938993A (de) |
AU (1) | AU2009214533B2 (de) |
BR (1) | BRPI0906611A8 (de) |
CA (1) | CA2712832C (de) |
DE (2) | DE102008008522A1 (de) |
DK (1) | DK2249804T3 (de) |
ES (1) | ES2619509T3 (de) |
IL (1) | IL207137A (de) |
MX (1) | MX2010008806A (de) |
PL (1) | PL2249804T3 (de) |
PT (1) | PT2249804T (de) |
RU (1) | RU2524644C2 (de) |
SG (1) | SG188146A1 (de) |
WO (1) | WO2009100716A2 (de) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082796A2 (de) | 2009-12-16 | 2011-07-14 | Magforce Nanotechnologies Ag | Temperaturabhängige aktivierung von katalytischen nukleinsäuren zur kontrollierten wirkstofffreisetzung |
WO2012119775A1 (de) | 2011-03-10 | 2012-09-13 | Magforce Ag | Computergestütztes simulationswerkzeug zur unterstützung bei der planung einer thermotherapie |
WO2013020701A2 (en) | 2011-08-10 | 2013-02-14 | Magforce Ag | Agglomerating magnetic alkoxysilane-coated nanoparticles |
JP2013536160A (ja) * | 2010-06-29 | 2013-09-19 | コーニンクレッカ フィリップス エヌ ヴェ | 鉄オレイン酸の合成及び使用 |
RU2616258C2 (ru) * | 2014-11-10 | 2017-04-13 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Способ получения полимерных наночастиц низкосиалированного эритропоэтина с высокой степенью сорбции для лечения неврологических заболеваний |
US9821045B2 (en) | 2008-02-13 | 2017-11-21 | President And Fellows Of Harvard College | Controlled delivery of TLR3 agonists in structural polymeric devices |
US9849193B2 (en) | 2013-02-08 | 2017-12-26 | University Of Louisville Research Foundation, Inc. | Nanoparticles for drug delivery |
EP3305334A1 (de) * | 2016-10-06 | 2018-04-11 | Universitätsklinikum Jena | Magnetische zusammensetzung und medizinisches material zur simulation von vaskularisierung in einer internen oder externen wunde des körpers |
US10137184B2 (en) | 2005-12-13 | 2018-11-27 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
WO2021152136A1 (en) | 2020-01-31 | 2021-08-05 | Magforce Ag | Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles |
US11150242B2 (en) | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
US11202759B2 (en) | 2010-10-06 | 2021-12-21 | President And Fellows Of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
US11278604B2 (en) | 2012-04-16 | 2022-03-22 | President And Fellows Of Harvard College | Mesoporous silica compositions comprising inflammatory cytokines comprising inflammatory cytokines for modulating immune responses |
US11555177B2 (en) | 2016-07-13 | 2023-01-17 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010026638A1 (ja) * | 2008-09-04 | 2010-03-11 | 株式会社ナノセラピー研究所 | 抗制御性t細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 |
JP5463531B2 (ja) * | 2009-07-22 | 2014-04-09 | 国立大学法人 東京大学 | Phd2発現抑制物質搭載ポリイオンコンプレックス |
CA2768552A1 (en) | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
ES2600229T3 (es) * | 2009-11-12 | 2017-02-07 | Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH | Nanopartículas magnéticas biocompatibles para el tratamiento de glioblastomas |
EP2608762B2 (de) | 2010-08-27 | 2020-05-13 | Sienna Biopharmaceuticals, Inc. | Zusammensetzungen und verfahren für gezielte wärmemodulation |
US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
US8944067B2 (en) * | 2010-12-15 | 2015-02-03 | Kci Licensing, Inc. | Targeted delivery of magnetically tagged active agents in combination with negative pressure wound therapy |
US10359552B2 (en) | 2011-01-17 | 2019-07-23 | University Of Utah Research Foundation | Methods, systems, and apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles |
US9606277B2 (en) | 2011-01-17 | 2017-03-28 | University Of Utah Research Foundation | Apparatus and methods for reducing frequency or severity of photophobic responses or modulating circadian cycles |
US9764157B2 (en) | 2011-01-17 | 2017-09-19 | University Of Utah Research Foundation | Methods, systems, and apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
EP2701745B1 (de) | 2011-04-28 | 2018-07-11 | President and Fellows of Harvard College | Injizierbare vorgeformte makroskopische 3d-gerüste für minimal invasive verabreichung |
WO2012154535A1 (en) * | 2011-05-06 | 2012-11-15 | Doktycz Mitchel J | Active materials for prevention and treatment of fouled surfaces |
EP2714073B1 (de) * | 2011-06-03 | 2021-03-10 | President and Fellows of Harvard College | Krebsimpfstoff zur in-situ-antigen-erzeugung |
CN102379762B (zh) * | 2011-08-02 | 2015-03-25 | 上海微创医疗器械(集团)有限公司 | 一种带凹槽的生物可降解支架及其制备方法 |
KR102025743B1 (ko) | 2011-12-16 | 2019-09-26 | 나노비오?스 | 금속성 및 산화하프늄 소재를 포함하는 나노입자, 이의 제조 및 용도 |
AU2013329450B2 (en) | 2012-10-11 | 2017-06-22 | Coronado Aesthetics, Llc | Silver nanoplate compositions and methods |
WO2014085651A1 (en) * | 2012-11-29 | 2014-06-05 | The Johns Hopkins University | A process for making iron oxide nanoparticle preparations for cancer hyperthermia |
US20140219926A1 (en) * | 2013-02-01 | 2014-08-07 | The Trustees Of Dartmouth College | Biodegradable Iron Oxide Nanoparticle Gel for Tumor Bed Therapy |
CN103203903A (zh) * | 2013-03-25 | 2013-07-17 | 海龙核材科技(江苏)有限公司 | 一种电场磁场下响应的传感材料及其制备方法 |
CA2914428C (en) * | 2013-06-04 | 2022-04-19 | Fumedica Ag | Cytotoxic substance for use in combination with radiotherapy in cancer treatment |
CN105431141A (zh) | 2013-06-20 | 2016-03-23 | 纳米生物技术公司 | 用于医学诊断的组合物及方法 |
EP2823858A1 (de) | 2013-07-12 | 2015-01-14 | Brossel, Rémy | System zur Erzeugung eines eingeschränkten Feldes, und medizinische Vorrichtung damit |
WO2015020936A1 (en) | 2013-08-06 | 2015-02-12 | Ut-Battelle, Llc | Local thermal actuation of material surfaces via micro- and nanowire heating for the prevention of cellular attachment and biological fouling |
US10234608B2 (en) | 2013-11-15 | 2019-03-19 | University Of Utah Research Foundation | Nanoparticle light filtering method and apparatus |
US10281627B2 (en) | 2013-11-15 | 2019-05-07 | University Of Utah Research Foundation | Nanoparticle light filtering method and apparatus |
CN103752849B (zh) * | 2014-02-13 | 2016-02-24 | 华东理工大学 | 制备稳定纳米银的方法 |
US9814631B2 (en) * | 2014-03-03 | 2017-11-14 | Sambhu Choudhury | Container for surgical absorbent articles |
WO2015161181A1 (en) | 2014-04-17 | 2015-10-22 | Boston Scientific Scimed, Inc. | Devices and methods for therapeutic heat treatment |
CN103989552B (zh) * | 2014-05-07 | 2015-10-28 | 江苏达胜伦比亚生物科技有限公司 | 一种医用水凝胶凉贴 |
CZ306793B6 (cs) * | 2014-08-21 | 2017-07-12 | Univerzita Tomáše Bati ve Zlíně | Biomateriál na bázi hydrogelu s magnetickými vlastnostmi a způsob jeho přípravy |
AR104806A1 (es) | 2015-05-28 | 2017-08-16 | Nanobiotix | Nanopartículas para uso como vacuna terapéutica |
EP3344301B1 (de) * | 2015-09-04 | 2020-09-02 | University of the Witwatersrand, Johannesburg | Biologisch abbaubares implantat |
CN108289856A (zh) | 2015-10-07 | 2018-07-17 | 波士顿科学国际有限公司 | 用以提高热疗的感应加热效率的具有不同居里温度的LaFeSiH磁性纳米粒子混合物 |
RU167739U1 (ru) * | 2015-12-02 | 2017-01-10 | Федеральное государственное бюджетное учреждение науки Красноярский научный центр Сибирского отделения Российской академии наук (ФГБУН КНЦ СО РАН) | Нанодиски для разрушения опухолевых клеток |
RU2742340C2 (ru) * | 2016-09-08 | 2021-02-04 | Шефер Кальк Гмбх Унд Ко. Кг | Содержащий соль кальция композиционный порошок с микроструктурированными частицами |
WO2018105779A1 (ko) * | 2016-12-07 | 2018-06-14 | 서울대학교산학협력단 | 바이오 패치, 바이오 히터, 바이오 센서, 및 바이오 전자 패치 장치 |
CZ2016804A3 (cs) * | 2016-12-16 | 2018-04-18 | Synthesia, A. S. | Supramolekulární komplex oxycelulózové matrice s taxolovým derivátem s postupným uvolňováním taxolového derivátu a jeho použití |
US20190350867A1 (en) * | 2016-12-27 | 2019-11-21 | Soon Kap Hahn | Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles |
DE102017214576A1 (de) * | 2017-08-21 | 2019-02-21 | Universität Bielefeld | Anorganisch-organischer Nanokomposit mit zellbiologischer und sensorischer Aktivität |
RU181004U1 (ru) * | 2017-11-14 | 2018-07-03 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный технический университет имени Гагарина Ю.А." (СГТУ имени Гагарина Ю.А.) | Пластинчатый дентальный имплантат для многопозиционного протезирования |
RU181003U1 (ru) * | 2017-11-14 | 2018-07-03 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный технический университет имени Гагарина Ю.А." (СГТУ имени Гагарина Ю.А.) | Пластинчатый дентальный имплантат для многопозиционного протезирования |
RU181002U1 (ru) * | 2017-12-25 | 2018-07-03 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный технический университет имени Гагарина Ю.А." (СГТУ имени Гагарина Ю.А.) | Пластинчатый дентальный имплантат для многопозиционного протезирования |
KR102200787B1 (ko) * | 2017-12-29 | 2021-01-12 | 한경대학교 산학협력단 | 나노셀룰로오스를 이용한 습윤성 탄력붕대 |
CN108912628A (zh) * | 2018-05-31 | 2018-11-30 | 苏州乔纳森新材料科技有限公司 | 一种插管用抗菌纳米材料的制备方法 |
RU189268U1 (ru) * | 2019-03-22 | 2019-05-17 | Артем Олегович Бахметьев | Акупунктурная игла |
RU189308U1 (ru) * | 2019-03-22 | 2019-05-21 | Артем Олегович Бахметьев | Трансдермальный пластырь |
KR102372213B1 (ko) * | 2019-09-09 | 2022-03-08 | 한국화학연구원 | 히알루론산 또는 그의 염 및 폴리페놀 화합물을 포함하는 수분해성 필름 |
CN111921003B (zh) * | 2020-09-04 | 2022-06-03 | 东南大学 | 一种磁响应热疗可控降解栓塞微球及其制备方法与应用 |
CN112972779B (zh) * | 2021-02-05 | 2022-07-12 | 武汉磁济科技有限公司 | 一种植入式柔性磁响应人工膀胱基体及其制造方法 |
CN112972778B (zh) * | 2021-02-05 | 2022-05-27 | 华中科技大学 | 一种人工膀胱铁磁复合物及其制备方法 |
CN112933288B (zh) * | 2021-02-08 | 2022-02-22 | 四川大学 | 兼具止血和术后抗肿瘤功能的交联止血海绵及其制备方法 |
DE102022115394A1 (de) | 2022-06-21 | 2023-12-21 | Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen | Implantat und Anordnung aufweisend eine Strahlungsquelle und ein Implantat |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005586A1 (en) * | 1999-07-16 | 2001-01-25 | Wm. Marsh Rice University | Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
WO2004045652A2 (en) * | 2002-11-15 | 2004-06-03 | Politecnico Di Torino | Biocompatible magnetic materials for the treatment of cancer by means of hyperthermia, and processes for their production |
WO2006015317A2 (en) * | 2004-07-30 | 2006-02-09 | Acrymed, Inc. | Antimicrobial devices and compositions |
WO2006037113A2 (en) * | 2004-09-28 | 2006-04-06 | The Hong Kong University Of Science And Technology | Multifunctional supramolecular hydrogels as biomaterials |
DE102005016873A1 (de) * | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
WO2006125452A1 (en) * | 2005-05-23 | 2006-11-30 | Universite De Geneve | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH31064A (en) * | 1990-09-07 | 1998-02-05 | Nycomed As Of Nycoveten | Polymers containing diester units. |
US5411730A (en) | 1993-07-20 | 1995-05-02 | Research Corporation Technologies, Inc. | Magnetic microparticles |
DE4428851C2 (de) | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
DE19614136A1 (de) | 1996-04-10 | 1997-10-16 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung agglomeratfreier nanoskaliger Eisenoxidteilchen mit hydrolysebeständigem Überzug |
JPH10328314A (ja) * | 1997-06-02 | 1998-12-15 | Nippon Electric Glass Co Ltd | 温熱治療用セメント材料及び温熱治療用インプラント材 |
JPH10337335A (ja) * | 1997-06-06 | 1998-12-22 | Nippon Electric Glass Co Ltd | 温熱治療用インプラント材 |
DE19726282A1 (de) | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
US20030073663A1 (en) * | 1997-06-25 | 2003-04-17 | David M Wiseman | Bioabsorbable medical devices from oxidized polysaccharides |
US6267782B1 (en) * | 1997-11-20 | 2001-07-31 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal |
DE10059151C2 (de) | 2000-11-29 | 2003-10-16 | Christoph Alexiou | Magnetische Partikel zur zielgerichteten regionalen Therapie und Verwendung derselben |
US6527693B2 (en) * | 2001-01-30 | 2003-03-04 | Implant Sciences Corporation | Methods and implants for providing radiation to a patient |
US20060057192A1 (en) | 2001-09-28 | 2006-03-16 | Kane Patrick D | Localized non-invasive biological modulation system |
DE10164309A1 (de) * | 2001-12-28 | 2003-07-10 | Fraunhofer Ges Forschung | Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle |
US7101394B2 (en) * | 2002-05-02 | 2006-09-05 | Boston Scientific Scimed, Inc. | Energetically-controlled delivery of biologically active material from an implanted medical device |
US20040136905A1 (en) * | 2002-10-15 | 2004-07-15 | Kent Thomas B. | Magnetically guided particles for radiative therapies |
DE10350248A1 (de) | 2003-10-28 | 2005-06-16 | Magnamedics Gmbh | Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik |
US20070196281A1 (en) | 2003-12-31 | 2007-08-23 | Sungho Jin | Method and articles for remote magnetically induced treatment of cancer and other diseases, and method for operating such article |
CA2553647A1 (en) | 2004-01-20 | 2005-08-04 | Alnis Biosciences, Inc. | Articles comprising magnetic material and bioactive agents |
FR2889449B1 (fr) | 2005-08-05 | 2011-06-10 | Khorionyx | Preparations implantables |
DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
WO2007095454A2 (en) * | 2006-02-10 | 2007-08-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Carbon-encased metal nanoparticles and sponges, methods of synthesis, and methods of use |
US20080213382A1 (en) * | 2007-01-19 | 2008-09-04 | Triton Biosystems, Inc. | Thermotherapy susceptors and methods of using same |
-
2008
- 2008-02-11 DE DE102008008522A patent/DE102008008522A1/de not_active Withdrawn
-
2009
- 2009-02-11 AU AU2009214533A patent/AU2009214533B2/en active Active
- 2009-02-11 BR BRPI0906611A patent/BRPI0906611A8/pt not_active IP Right Cessation
- 2009-02-11 MX MX2010008806A patent/MX2010008806A/es active IP Right Grant
- 2009-02-11 CA CA2712832A patent/CA2712832C/en active Active
- 2009-02-11 PL PL09711314T patent/PL2249804T3/pl unknown
- 2009-02-11 EP EP09711314.6A patent/EP2249804B1/de active Active
- 2009-02-11 RU RU2010136311/15A patent/RU2524644C2/ru active
- 2009-02-11 DK DK09711314.6T patent/DK2249804T3/en active
- 2009-02-11 JP JP2010546211A patent/JP5649455B2/ja active Active
- 2009-02-11 DE DE112009000905T patent/DE112009000905A5/de not_active Withdrawn
- 2009-02-11 PT PT97113146T patent/PT2249804T/pt unknown
- 2009-02-11 ES ES09711314.6T patent/ES2619509T3/es active Active
- 2009-02-11 KR KR1020107017850A patent/KR101581973B1/ko active IP Right Grant
- 2009-02-11 CN CN2009801043533A patent/CN101938993A/zh active Pending
- 2009-02-11 WO PCT/DE2009/000196 patent/WO2009100716A2/de active Application Filing
- 2009-02-11 US US12/864,793 patent/US20110223255A1/en not_active Abandoned
- 2009-02-11 SG SG2013010590A patent/SG188146A1/en unknown
-
2010
- 2010-07-21 IL IL207137A patent/IL207137A/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005586A1 (en) * | 1999-07-16 | 2001-01-25 | Wm. Marsh Rice University | Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
WO2004045652A2 (en) * | 2002-11-15 | 2004-06-03 | Politecnico Di Torino | Biocompatible magnetic materials for the treatment of cancer by means of hyperthermia, and processes for their production |
WO2006015317A2 (en) * | 2004-07-30 | 2006-02-09 | Acrymed, Inc. | Antimicrobial devices and compositions |
WO2006037113A2 (en) * | 2004-09-28 | 2006-04-06 | The Hong Kong University Of Science And Technology | Multifunctional supramolecular hydrogels as biomaterials |
DE102005016873A1 (de) * | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
WO2006125452A1 (en) * | 2005-05-23 | 2006-11-30 | Universite De Geneve | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11096997B2 (en) | 2005-12-13 | 2021-08-24 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
US10137184B2 (en) | 2005-12-13 | 2018-11-27 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
US10149897B2 (en) | 2005-12-13 | 2018-12-11 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
US10258677B2 (en) | 2008-02-13 | 2019-04-16 | President And Fellows Of Harvard College | Continuous cell programming devices |
US10568949B2 (en) | 2008-02-13 | 2020-02-25 | President And Fellows Of Harvard College | Method of eliciting an anti-tumor immune response with controlled delivery of TLR agonists in porous polymerlc devices |
US10328133B2 (en) | 2008-02-13 | 2019-06-25 | President And Fellows Of Harvard College | Continuous cell programming devices |
US9821045B2 (en) | 2008-02-13 | 2017-11-21 | President And Fellows Of Harvard College | Controlled delivery of TLR3 agonists in structural polymeric devices |
US9517272B2 (en) | 2009-12-16 | 2016-12-13 | Magforce Ag | Temperature dependent activation of catalytic nucleic acids for controlled active substance release |
WO2011082796A2 (de) | 2009-12-16 | 2011-07-14 | Magforce Nanotechnologies Ag | Temperaturabhängige aktivierung von katalytischen nukleinsäuren zur kontrollierten wirkstofffreisetzung |
JP2013536160A (ja) * | 2010-06-29 | 2013-09-19 | コーニンクレッカ フィリップス エヌ ヴェ | 鉄オレイン酸の合成及び使用 |
US11202759B2 (en) | 2010-10-06 | 2021-12-21 | President And Fellows Of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
US8949088B2 (en) | 2011-03-10 | 2015-02-03 | Magforce Ag | Computer-aided simulation tool for providing assistance in the planning of thermotherapy |
US9844680B2 (en) | 2011-03-10 | 2017-12-19 | Magforce Ag | Computer-aided simulation tool for providing assistance in the planning of thermotherapy |
WO2012119775A1 (de) | 2011-03-10 | 2012-09-13 | Magforce Ag | Computergestütztes simulationswerkzeug zur unterstützung bei der planung einer thermotherapie |
US9962442B2 (en) | 2011-08-10 | 2018-05-08 | Magforce Ag | Agglomerating magnetic alkoxysilane-coated nanoparticles |
WO2013020701A2 (en) | 2011-08-10 | 2013-02-14 | Magforce Ag | Agglomerating magnetic alkoxysilane-coated nanoparticles |
DE202012012795U1 (de) | 2011-08-10 | 2013-11-21 | Magforce Ag | Agglomerierende Magnetische alkoxysilan-beschichtete Nanopartikel |
EP3038115A1 (de) | 2011-08-10 | 2016-06-29 | MagForce AG | Agglomeration magnetischer alkoxysilanbeschichteter nanopartikel |
US9408912B2 (en) | 2011-08-10 | 2016-08-09 | Magforce Ag | Agglomerating magnetic alkoxysilane-coated nanoparticles |
US11278604B2 (en) | 2012-04-16 | 2022-03-22 | President And Fellows Of Harvard College | Mesoporous silica compositions comprising inflammatory cytokines comprising inflammatory cytokines for modulating immune responses |
US9849193B2 (en) | 2013-02-08 | 2017-12-26 | University Of Louisville Research Foundation, Inc. | Nanoparticles for drug delivery |
US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
RU2616258C2 (ru) * | 2014-11-10 | 2017-04-13 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Способ получения полимерных наночастиц низкосиалированного эритропоэтина с высокой степенью сорбции для лечения неврологических заболеваний |
US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
US11150242B2 (en) | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
US11555177B2 (en) | 2016-07-13 | 2023-01-17 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
EP3305334A1 (de) * | 2016-10-06 | 2018-04-11 | Universitätsklinikum Jena | Magnetische zusammensetzung und medizinisches material zur simulation von vaskularisierung in einer internen oder externen wunde des körpers |
WO2021152136A1 (en) | 2020-01-31 | 2021-08-05 | Magforce Ag | Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles |
Also Published As
Publication number | Publication date |
---|---|
CA2712832C (en) | 2016-05-17 |
BRPI0906611A8 (pt) | 2019-01-29 |
BRPI0906611A2 (pt) | 2015-07-14 |
CN101938993A (zh) | 2011-01-05 |
AU2009214533A1 (en) | 2009-08-20 |
PL2249804T3 (pl) | 2017-07-31 |
EP2249804B1 (de) | 2016-12-14 |
IL207137A0 (en) | 2010-12-30 |
EP2249804A2 (de) | 2010-11-17 |
JP5649455B2 (ja) | 2015-01-07 |
ES2619509T3 (es) | 2017-06-26 |
PT2249804T (pt) | 2017-03-20 |
IL207137A (en) | 2015-02-26 |
WO2009100716A3 (de) | 2010-09-23 |
RU2524644C2 (ru) | 2014-07-27 |
CA2712832A1 (en) | 2009-08-20 |
KR20100117602A (ko) | 2010-11-03 |
JP2011511684A (ja) | 2011-04-14 |
KR101581973B1 (ko) | 2015-12-31 |
DE102008008522A1 (de) | 2009-08-13 |
DE112009000905A5 (de) | 2011-01-20 |
AU2009214533B2 (en) | 2015-01-29 |
SG188146A1 (en) | 2013-03-28 |
RU2010136311A (ru) | 2012-03-20 |
US20110223255A1 (en) | 2011-09-15 |
MX2010008806A (es) | 2010-12-21 |
DK2249804T3 (en) | 2017-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2249804B1 (de) | Implantierbare nanopartikel-enthaltende produkte | |
Ali et al. | A review on chitosan and its nanocomposites in drug delivery | |
EP1871423B1 (de) | Nanopartikel-wirkstoff-konjugate | |
DE112006004066B4 (de) | Magnetischer Träger und medizinisches Präparat zur kontrollierbaren Zuführung und Freisetzung von Wirkstoffen, Herstellungsverfahren dafür und Behandlungsverfahren unter Verwendung davon | |
DE69916031T2 (de) | Asorbierbare mikropartikel | |
KR20140084144A (ko) | 출혈 제어 및 약물 전달을 위한 나노입자 | |
Argenta et al. | Hydrogel nanocomposite systems: physico-chemical characterization and application for drug-delivery systems | |
Yassue-Cordeiro et al. | Chitosan-based nanocomposites for drug delivery | |
Singh et al. | Nanomaterials: compatibility towards biological interactions | |
US20120035531A1 (en) | On-demand and reversible drug release by external cue | |
US9713702B2 (en) | Methods of electric field induced delivery of compounds, compositions used in delivery, and systems of delivery | |
Piatkowski et al. | Application of Poly (aspartic acid) and its Derivatives in Medicine and Pharmacy | |
KR20120059721A (ko) | 단백질 약물 전달용 다당류 나노겔 및 이의 제조방법 | |
Balan et al. | Chitosan-based systems for theranostic applications | |
Cholkar et al. | Therapeutic Applications of Polymeric Materials | |
Banerjee et al. | Nanomaterials regenerative medicine and tissue engineering | |
Rostami | Chitosan‐Based Nanoparticles for Drug Delivery | |
Mondal et al. | Nanostructured Materials for Tissue Engineering | |
Shahid et al. | Nanocomposite Hydrogels-A Promising Approach towards Enhanced Bioavailability and Controlled Drug Delivery | |
Patra et al. | Biological aspects of polymer nanocomposites | |
Dahman et al. | Nanotechnology and its Applications in Biomedical Engineering | |
del Castillo Castro et al. | Nanocomposite hydrogels as drug delivery systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980104353.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09711314 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5075/DELNP/2010 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2009711314 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009711314 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009214533 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 207137 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2712832 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20107017850 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010546211 Country of ref document: JP Ref document number: MX/A/2010/008806 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009214533 Country of ref document: AU Date of ref document: 20090211 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010136311 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12864793 Country of ref document: US |
|
REF | Corresponds to |
Ref document number: 112009000905 Country of ref document: DE Date of ref document: 20110120 Kind code of ref document: P |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8629 |
|
ENP | Entry into the national phase |
Ref document number: PI0906611 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100730 |